PHILADELPHIA, PA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)NATIONAL DISEASE RESEARCH INTERCHANGE, founded in 1988, is a mid-sized nonprofit in the Medical Research sector that reported $11.3M in total revenue in fiscal year 2024. Revenue surged 23% from the prior year, signaling strong growth momentum. Expenses of $10.6M left a modest 6% surplus.
THE MISSION OF NDRI IS TO PROVIDE HUMAN BIOSPECIMENS WORLDWIDE TO ADVANCE BIOMEDICAL/BIOSCIENCE RESEARCH AND DEVELOPMENT AND EDUCATION IN THE LIFE SCIENCES.
HUMAN TISSUE AND RESOURCE FOR RESEARCH: NDRI RECEIVED A FEDERAL AWARD FOR THE HUMAN TISSUE AND ORGAN RESOURCE FOR THE PROCUREMENT AND DISTRIBUTION OF NORMAL AND DISEASED HUMAN ORGANS AND TISSUES TO...
HUMAN TISSUE AND RESOURCE FOR RESEARCH: NDRI RECEIVED A FEDERAL AWARD FOR THE HUMAN TISSUE AND ORGAN RESOURCE FOR THE PROCUREMENT AND DISTRIBUTION OF NORMAL AND DISEASED HUMAN ORGANS AND TISSUES TO ADVANCE BIOMEDICAL SCIENCE.
PARTNER PROGRAM: COORDINATES VARIOUS HUMAN ORGAN AND TISSUE PROCUREMENT PROGRAMS WITH THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO ACCELERATE RESEARCH AND DEVELOPMENT. SEVERAL OF THESE PROGRAMS...
PARTNER PROGRAM: COORDINATES VARIOUS HUMAN ORGAN AND TISSUE PROCUREMENT PROGRAMS WITH THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO ACCELERATE RESEARCH AND DEVELOPMENT. SEVERAL OF THESE PROGRAMS HAVE LED TO THE DEVELOPMENT OF TREATMENTS FOR MEDICAL CONDITIONS SUCH AS LUNG DISEASE, DIABETES, AND CANCER, TO NAME ONLY A FEW. OTHER PARTNER PROGRAMS HAVE LED TO THE CREATION OF RESEARCH TOOLS FOR USE IN NUMEROUS TOXICOLOGY AND DRUG DISCOVERY PLATFORMS.
RESEARCH COLLABORATIONS WITH FOUNDATION AND PATIENT ADVOCACY GROUPS (PAG): NDRI MAINTAINS COLLABORATIONS WITH A VARIETY OF DIFFERENT FOUNDATION AND PATIENT ADVOCACY GROUPS FOCUSED ON THE ADVANCEMENT...
RESEARCH COLLABORATIONS WITH FOUNDATION AND PATIENT ADVOCACY GROUPS (PAG): NDRI MAINTAINS COLLABORATIONS WITH A VARIETY OF DIFFERENT FOUNDATION AND PATIENT ADVOCACY GROUPS FOCUSED ON THE ADVANCEMENT OF RESEARCH IN EACH OF THEIR RESPECTIVE AREAS OF INTEREST. THESE COLLABORATIONS BRING TOGETHER PATIENTS, PAGS, FOUNDATIONS, NDRI AND THE PHARMACEUTICAL INDUSTRY TO HELP ADVANCE R&D UTILIZING CRITICAL HUMAN BIOSPECIMENS GIFTED BY PATIENTS/DONORS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $11,282,464 | $9,146,487 | +0.2% |
| Expenses | $10,583,538 | $9,254,872 | +0.1% |
| Net Income | $698,926 | $-108,385 | -7.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| WILLIAM LEINWEBER | PRESIDENT & CEO | 37.50 |
Officer
Director
|
$432,567 | $69,142 | $501,709 |
| MARY JC HENDRIX | CHAIR OF THE BOARD | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| DAVID M ALBERT | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| SHAWN BLACKBURN | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| SULAYMAN DIB-HAJJ | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MEGAN KASIMATIS SINGLETON | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| VERA KRYMSKAYA | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| PAUL M LIEBERMAN | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBERT MARCANTUONO | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JESSICA MULHOLLAND | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| HOWARD M NATHAN | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| LOUIS PHILIPSON | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ARTHUR H RUBENSTEIN | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JIM VAUGHT | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL WHITE | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| DEANNE TAYLOR | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| RICHARD HASZ JR | BOARD MEMBER (EFF NOV 2024) | 1.00 |
Director
|
$0 | $0 | $0 |
| THOMAS MALECKI | CFO; VP, ADMINISTRATION | 37.50 |
Officer
|
$214,583 | $6,200 | $220,783 |
| THOMAS BELL | CHIEF SCIENTIFIC OFFICER | 37.50 |
Highest
|
$248,259 | $12,853 | $261,112 |
| MELISSA W VONDRAN | SR VP, OPERATIONS & DIRECTOR BIOREPOSITORY | 35.00 |
Highest
|
$190,478 | $7,472 | $197,950 |
| SABOOR A SHAD | DIRECTOR, TISSUE SOURCE SITE MGMT | 37.50 |
Highest
|
$112,347 | $14,773 | $127,120 |
| DANA R ROSALES | DIRECTOR, FULFILLMENT | 37.50 |
Highest
|
$115,055 | $40,365 | $155,420 |
| SUSAN MCGOVERN | MANAGER HUMAN RESOURCES | 37.50 |
Highest
|
$107,589 | $18,555 | $126,144 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $11,282,464 | $10,583,538 | $7,101,587 | $698,926 |
| 2023 | $9,146,487 | $9,254,872 | $7,181,811 | $-108,385 |
| 2022 | $7,402,515 | $8,132,656 | $6,908,115 | $-730,141 |
| 2021 | $7,072,153 | $7,003,538 | $6,059,781 | $68,615 |
| 2020 | $6,460,315 | $7,265,227 | $6,399,365 | $-804,912 |
| 2019 | $7,121,789 | $7,214,782 | $6,065,530 | $-92,993 |
| 2018 | $7,408,450 | $7,222,387 | $3,796,622 | $186,063 |
Compare NATIONAL DISEASE RESEARCH INTERCHANGE with other nonprofits in Pennsylvania and across the country.